Naureen Quibria

Stock Analyst at Capital One

(n/a)

# 4,568

Out of 4,944 analysts

9

Total ratings

11.11%

Success rate

-45.21%

Average return

Main Sectors:

Top Industries:

Stocks Rated by Naureen Quibria

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	BMEA Biomea Fusion	Initiates: Overweight	$25	$1.72	+1,353.49%	1	Aug 29, 2024
	IMMP Immutep	Initiates: Overweight	$10	$1.74	+474.71%	1	May 17, 2024
	ERAS Erasca	Initiates: Overweight	$8	$1.63	+392.31%	1	Mar 11, 2024
	CARM Carisma Therapeutics	Initiates: Overweight	$10	$0.29	+3,312.97%	1	Oct 3, 2023
	IMCR Immunocore Holdings	Initiates: Overweight	$84	$33.00	+154.55%	1	Aug 16, 2023
	DAWN Day One Biopharmaceuticals	Initiates: Overweight	$40	$6.21	+544.12%	1	Feb 8, 2023
	FENC Fennec Pharmaceuticals	Initiates: Overweight	$11	$9.11	+20.75%	1	Sep 7, 2022
	GNTA Genenta Science	Initiates: Buy	$21	$3.20	+556.25%	1	Jan 13, 2022
	KZIA Kazia Therapeutics	Initiates: Buy	$900	$8.33	+10,707.57%	1	Oct 14, 2021

Biomea Fusion

Aug 29, 2024

Initiates: Overweight

Price Target: $25

Current: $1.72

Upside: +1,353.49%

Immutep

May 17, 2024

Initiates: Overweight

Price Target: $10

Current: $1.74

Upside: +474.71%

Erasca

Mar 11, 2024

Initiates: Overweight

Price Target: $8

Current: $1.63

Upside: +392.31%

Carisma Therapeutics

Oct 3, 2023

Initiates: Overweight

Price Target: $10

Current: $0.29

Upside: +3,312.97%

Immunocore Holdings

Aug 16, 2023

Initiates: Overweight

Price Target: $84

Current: $33.00

Upside: +154.55%

Day One Biopharmaceuticals

Feb 8, 2023

Initiates: Overweight

Price Target: $40

Current: $6.21

Upside: +544.12%

Fennec Pharmaceuticals

Sep 7, 2022

Initiates: Overweight

Price Target: $11

Current: $9.11

Upside: +20.75%

Genenta Science

Jan 13, 2022

Initiates: Buy

Price Target: $21

Current: $3.20

Upside: +556.25%

Kazia Therapeutics

Oct 14, 2021

Initiates: Buy

Price Target: $900

Current: $8.33

Upside: +10,707.57%